Fig. 1

CHIT-1 levels in CSF of ALS patients and controls. ELISA showed increased levels of CHIT-1 compared to N-CSF and NALS-CSF (****p < 0.0001 vs. N-CSF and ^$$p < 0.01 vs NALS-CSF) (a). Receiver operating curve (ROC) analysis (b). Increased levels of CHIT-1 in CSF of patients with lesser disease duration (****p < 0.0001 N-CSF vs. ALS-CSF up to 12 months, *p < 0.05 N-CSF vs. ALS-CSF > 12 months and **p < 0.01 ALS-CSF up to 12 months vs. ALS-CSF > 12 months (c). Correlation between CHIT-1 levels and disease duration (d). Increased level of CHIT-1 in definite cases compared to probable/possible cases of ALS (**p < 0.01 probable/possible vs. definite) (e). No significant difference was noticed between male vs. female (f) and bulbar vs. limb onset (g) of ALS. Correlation between CHIT-1 levels and ALS-FRS score (h)